睿知中国疾病研究地图
候选清单0

武汉华中科技大学同济医学院

华中科技大学同济医学院附属协和医院

Union Hospital

在本站收录的 53 种疾病中,这家医院列在其中 34 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

华中科技大学同济医学院附属协和医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma11 篇牵头论文牵头 1 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文牵头 1 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma144 篇牵头论文牵头 6 项开放试验
  4. 胃癌Stomach cancer78 篇牵头论文牵头 9 项开放试验
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
  7. 脊索瘤Chordoma1 篇牵头论文
  8. 骨肉瘤Osteosarcoma25 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour18 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma8 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  12. 多发性骨髓瘤Multiple myeloma30 篇牵头论文牵头 5 项开放试验
  13. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia3 篇牵头论文牵头 2 项开放试验
  14. 再生障碍性贫血Aplastic anaemia2 篇牵头论文牵头 1 项开放试验
  15. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis8 篇牵头论文
  16. 血友病 AHaemophilia A1 篇牵头论文
  17. 范可尼贫血Fanconi anaemia1 篇牵头论文
  18. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder1 篇牵头论文
  19. IgG4相关性疾病IgG4-related disease0 篇牵头论文
  20. 重症肌无力Myasthenia gravis0 篇牵头论文牵头 1 项开放试验
  21. 烟雾病Moyamoya disease2 篇牵头论文
  22. 胆道闭锁Biliary atresia7 篇牵头论文
  23. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  24. 大动脉炎Takayasu arteritis1 篇牵头论文
  25. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  26. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis0 篇牵头论文
  27. 白塞病Behçet disease0 篇牵头论文
  28. IgA 肾病IgA nephropathy2 篇牵头论文牵头 1 项开放试验
  29. 成骨不全症Osteogenesis imperfecta1 篇牵头论文
  30. 原发性胆汁性胆管炎Primary biliary cholangitis3 篇牵头论文
  31. 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
  32. 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
  33. 先天性巨结肠Hirschsprung disease8 篇牵头论文
  34. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、肝豆状核变性、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.5%。

牵头论文
11
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 5520222023: 2220232024: 1120242025: 002025

武汉有 6 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 8

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-09
    登记号
    NCT07177443

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  2. 正在招募
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2026-07
    登记号
    NCT07528183

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 3 家列出的医院为研究中心南宁、广州、武汉、福州

  3. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  4. 正在招募
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    分期
    II期
    开始
    2025-04
    登记号
    NCT06839066

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙

  5. 正在招募
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    分期
    II期
    开始
    2024-01
    登记号
    NCT05956587

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心临沂、南昌、天津、广州、杭州、柳州、武汉、福州、西安、郑州、重庆

  6. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

  7. 正在招募
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2024-03
    登记号
    NCT06301165

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 8 家列出的医院为研究中心东莞、佛山、广州、武汉、深圳

  8. 正在招募
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    分期
    I期
    开始
    2021-11
    登记号
    NCT05194982

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心广州、武汉、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题放疗技术诱导/同步化疗复发与转移
论文中的科室病理/检验科耳鼻喉/头颈外科肿瘤内科影像/核医学科
牵头的论文11
  1. Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis.2024Cell death and differentiation
  2. Nomograms incorporating primary tumor response at mid-radiotherapy to predict survival in locoregionally advanced nasopharyngeal carcinoma.2023Head & neck
  3. Down-regulated lncRNA ROR in tumor-educated platelets as a liquid-biopsy biomarker for nasopharyngeal carcinoma.2023Journal of cancer research and clinical oncology免费全文
  4. Tumor factors associated with in-field failure for nasopharyngeal carcinoma after intensity-modulated radiotherapy.2022Head & neck
  5. Prognostic and clinicopathological significance of lymphocyte-to-monocyte ratio in patients with nasopharyngeal carcinoma.2022Head & neck
  6. Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing.2022Oral oncology
  7. Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.2022Oral oncology
  8. A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone.2022PloS one免费全文
  9. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.2021Annals of palliative medicine
  10. Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China.2021Current medical science
  11. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study.2021European journal of nuclear medicine and molecular imaging
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
  1. Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma正在招募NCT07177443牵头方III期2025-09 启动
  2. Pembrolizumab + MRGOO3 as Neoadjuvant in NPC进行中,不再招募NCT07267338牵头方II期2026-02 启动
  3. The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors进行中,不再招募NCT07890038牵头方2026-06 启动
  4. Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma状态不明NCT05790200牵头方II期2023-04 启动
  5. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma正在招募NCT07528183研究中心II期2026-07 启动
  6. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  7. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy正在招募NCT06839066研究中心II期2025-04 启动
  8. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  9. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors正在招募NCT05956587研究中心II期2024-01 启动
  10. TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma正在招募NCT06301165研究中心II期2024-03 启动
  11. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor正在招募NCT05194982研究中心I期2021-11 启动
  12. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  13. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
  14. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma进行中,不再招募NCT05979961研究中心III期2023-09 启动
  15. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma已完成NCT05563480研究中心II期2022-10 启动
  16. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma进行中,不再招募NCT04907370研究中心III期2021-08 启动
  17. Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma已完成NCT03984357研究中心II期2020-03 启动
  18. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors已完成NCT04215978研究中心I期2020-01 启动
  19. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
  20. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT03427827研究中心III期2018-07 启动
  21. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  22. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma状态不明NCT03700476研究中心III期2018-12 启动
  23. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma状态不明NCT02633176研究中心III期2015-01 启动
  24. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)34
  1. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncology论文
  2. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncology论文
  3. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncology论文
  4. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncology会议摘要
  5. DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning2025Image and Vision Computing论文
  6. Expert-Constrained Deep Learning Framework for Nasopharyngeal Carcinoma Automated Target Delineation2025International Journal of Radiation Oncology*Biology*Physics论文
  7. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  8. Unsupervised deep learning model for fast energy layer pre-selection of delivery-efficient proton arc therapy plan optimization of nasopharyngeal carcinoma2025arXiv (Cornell University)预印本
  9. 416P A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with chemotherapy for the treatment of anti-PD-1 resistant, recurrent, or metastatic nasopharyngeal carcinoma (R/M NPC)2024Annals of Oncology论文
  10. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncology会议摘要
  11. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncology会议摘要
  12. Anatomical and Dosimetric Variations during VMAT in Patients with Locally Advanced Nasopharyngeal Carcinoma after Induction Therapy: Implications for Adaptive Radiation Therapy2024International Journal of Radiation Oncology*Biology*Physics论文
  13. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncology会议摘要
  14. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncology会议摘要
  15. Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.2024Journal of Clinical Oncology会议摘要
  16. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.2024Journal of Clinical Oncology会议摘要
  17. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncology会议摘要
  18. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncology会议摘要
  19. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  20. Radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma: Updated results from a multicenter, open-label, non-inferiority, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  21. A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.2023Journal of Clinical Oncology会议摘要
  22. A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).2023Journal of Clinical Oncology会议摘要
  23. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncology论文
  24. Camrelizumab plus taxanes and cisplatin (TP) chemotherapy or TP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma2023Research Square预印本
  25. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncology会议摘要
  26. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2023Research Square预印本
  27. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncology会议摘要
  28. Standard Therapy vs. Individualized Therapy in Elderly Locally Advanced Nasopharyngeal Carcinoma: A Real-World Study2023International Journal of Radiation Oncology*Biology*Physics论文
  29. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Research会议摘要
  30. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2022Research Square预印本
  31. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.2022Journal of Clinical Oncology会议摘要
  32. AccuLearning: A User-Friendly Deep Learning Auto-Segmentation Platform for Radiotherapy2021International Journal of Radiation Oncology*Biology*Physics论文
  33. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncology会议摘要
  34. Patterns of Local-Regional Relapse Following Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physics论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 2220242025: 332025

武汉有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
    分期
    II期
    开始
    2026-02
    登记号
    NCT07403435

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  2. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题新辅助与综合治疗免疫治疗放疗
论文中的科室影像/核医学科消化/肝病科
牵头的论文8
  1. NCF2 drives tumor progression and metastasis through NR2F2/LATS2/YAP1 axis in esophageal squamous cell carcinoma.2025Cancer letters
  2. The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients.2025Frontiers in immunology免费全文
  3. Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study.2024BMC medical imaging免费全文
  5. Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma.2024International immunopharmacology
  6. Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.2023BMC cancer免费全文
  7. Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK.2023Thoracic cancer免费全文
  8. Exploration of an effective training system for diagnosis of superficial esophageal squamous cell carcinoma with magnifying narrow-band imaging: Prospective research.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC即将招募NCT07403435牵头方II期2026-02 启动
  2. Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer状态不明NCT04776590牵头方II期2021-01 启动
  3. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  4. A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors已完成NCT06549816研究中心I期2024-08 启动
  5. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  6. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma已完成NCT04974047研究中心II期2021-08 启动
  7. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  8. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors状态不明NCT05602792研究中心I/II期2020-04 启动
  9. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  10. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  11. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  12. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  13. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)12
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncology会议摘要
  3. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  4. Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial2024International Journal of Radiation Oncology*Biology*Physics论文
  5. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncology论文
  6. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncology会议摘要
  7. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  8. 163P Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma: An interim analysis of the prospective, single-arm, phase II trial2022Immuno-Oncology Technology论文
  9. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  10. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  11. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  12. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 144 篇,占 1.0%。

牵头论文
144
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 191920212022: 313120222023: 353520232024: 353520242025: 22222025

武汉有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
    分期
    II期
    开始
    2026-10
    登记号
    NCT07776080

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  2. 正在招募
    Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
    分期
    未注明
    开始
    2025-07
    登记号
    NCT07059936

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  3. 正在招募
    Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
    分期
    未注明
    开始
    2025-11
    登记号
    NCT07235410

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  4. 正在招募
    HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2024-01
    登记号
    NCT06244225

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  5. 正在招募
    Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
    分期
    早期I期
    开始
    2023-09
    登记号
    NCT06383520

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  6. 即将招募
    Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
    分期
    早期I期
    开始
    2026-01
    登记号
    NCT07352345

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  7. 正在招募
    A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
    分期
    II期
    开始
    2025-07
    登记号
    NCT07052253

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心武汉

  8. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  9. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  10. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  11. 即将招募
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    分期
    不分期
    开始
    2025-06
    登记号
    NCT07010588

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:北京大学人民医院;另有 8 家列出的医院为研究中心北京、哈尔滨、武汉、济南、西安、重庆、长春、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题局部治疗(消融、TACE、HAIC)免疫与靶向药物复发与预后
论文中的科室影像/核医学科普外/肝胆胰外科消化/肝病科病理/检验科
牵头的论文144
  1. Recent Advances in Embolic Agents for Transarterial Chemoembolization of Hepatocellular Carcinoma.2026Advanced healthcare materials
  2. Hyaluronidase optimizes TACE in hepatocellular carcinoma by remodeling tumor stroma and enhancing chemotherapy penetration.2026International journal of biological macromolecules
  3. Development and validation of a score model for predicting the risk of first esophagogastric variceal hemorrhage and mortality in patients with hepatocellular carcinoma.2025Annals of medicine免费全文
  4. RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma.2025BMC cancer免费全文
  5. Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE.2025BMC gastroenterology免费全文
  6. Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma.2025BMC gastroenterology免费全文
  7. Feasibility, efficacy, and safety of ventral caudal artery access for transarterial chemoembolization in a rat hepatocellular carcinoma model.2025BMC gastroenterology免费全文
  8. Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.2025BMC medicineRCT免费全文
  9. Ellagic acid mediated pyroptosis in hepatocellular carcinoma via the ESR1/G6PD pathway.2025Biochemical pharmacology
  10. Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.2025Cell death & disease免费全文
  11. STAT3 orchestrates immune dynamics in hepatocellular carcinoma: A pivotal nexus in tumor progression.2025Critical reviews in oncology/hematology
  12. Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements.2025Current oncology (Toronto, Ont.)免费全文
  13. [68Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma.2025European journal of nuclear medicine and molecular imaging
  14. Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis.2025International immunopharmacology
  15. The Dual Role of TRADD in Liver Disease: From Cell Death Regulation to Inflammatory Microenvironment Remodeling.2025International journal of molecular sciences免费全文
  16. Exosome-Delivered circFOXP1 Upregulates Autophagy and Promotes Hepatocellular Carcinoma Progression Through Its Encoded p196 Protein Targeting the KHDRBS3/ULK1 Axis.2025International journal of nanomedicine免费全文
  17. Protein Induced by Vitamin K Absence or Antagonist-II: Significantly Elevated in Obstructive Jaundice and Sepsis Patients Without Hepatocellular Carcinoma.2025Journal of clinical laboratory analysis免费全文
  18. COX-2/PGE2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation.2025Journal of experimental & clinical cancer research : CR免费全文
  19. Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.2025Nature communications免费全文
  20. A glucose kinase-independent HK2 activity prevents TNF-induced cell death by phosphorylating RIPK1.2025Nature communications免费全文
  21. [Expression of Concern] Reciprocal negative feedback loop between EZH2 and miR‑101‑1 contributes to miR‑101 deregulation in hepatocellular carcinoma.2025Oncology reports免费全文
  22. The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery.2025Scientific reports免费全文
  23. Prognostic impact of extracellular volume fraction derived from equilibrium contrast-enhanced CT in HCC patients receiving immune checkpoint inhibitors.2025Scientific reports免费全文
  24. Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular2025World journal of surgical oncology免费全文
  25. Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study.2024Anti-cancer agents in medicinal chemistry
  26. Construction of a random survival forest model based on a machine learning algorithm to predict early recurrence after hepatectomy for adult hepatocellular carcinoma.2024BMC cancer免费全文
  27. Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma.2024BMC cancer免费全文
  28. Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma.2024BMC cancer免费全文
  29. Nomograms established for predicting microvascular invasion and early recurrence in patients with small hepatocellular carcinoma.2024BMC cancer免费全文
  30. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.2024BMC cancer免费全文
  31. Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails.2024BMC gastroenterology免费全文
  32. Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.2024BMJ open免费全文
  33. Recent advances in hepatocellular carcinoma-targeted nanoparticles.2024Biomedical materials (Bristol, England)
  34. Parapharyngeal and maxillary metastasis in hepatocellular carcinoma as the first presentation: a rare case.2024Brazilian journal of otorhinolaryngology免费全文
  35. Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  36. Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2.2024Cellular signalling
  37. Cell Cycle-Related LncRNA-Based Prognostic Model for Hepatocellular Carcinoma: Integrating Immune Microenvironment and Treatment Response.2024Current medical science
  38. Incidence, Risk Factors, and Prognosis of Patients with Hepatocellular Carcinoma and Brain Metastases.2024Current medical science
  39. TRAF2 decrease promotes the TGF-β-mTORC1 signal in MAFLD-HCC through enhancing AXIN1-mediated Smad7 degradation.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  40. Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience.2024Frontiers in immunology免费全文
  41. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.2024Frontiers in immunology免费全文
  42. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.2024Frontiers in immunology免费全文
  43. Blocking TGFβR synergistically enhances anti-tumor effects of anti-PD-1 antibody in a mouse model of incomplete thermal ablation.2024International immunopharmacology
  44. Radiofrequency hyperthermia enhances the effect of OK-432 for Hepatocellular carcinoma by activating of TLR4-cGAS-STING pathway.2024International immunopharmacology
  45. Exosomal SLC16A1-AS1-induced M2 macrophages polarization facilitates hepatocellular carcinoma progression.2024International journal of biological sciences免费全文
  46. The m6A modification-mediated positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma.2024International journal of biological sciences免费全文
  47. Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma.2024International journal of nanomedicine免费全文
  48. Synergistic Effects of Nanoscale CaO2 Combined with PD-1 Inhibitors in the Treatment of Hepatocellular Carcinoma: A Promising Combination.2024International journal of nanomedicine免费全文
  49. Relaxin combined with transarterial chemoembolization achieved synergistic effects and inhibited liver cancer metastasis in a rabbit VX2 model.2024Journal of cancer research and clinical oncology免费全文
  50. Multi-Omics Profiling and Experimental Verification of Lysosomes-Related Genes in Hepatocellular Carcinoma.2024Journal of cellular and molecular medicine免费全文
  51. The liquid-liquid phase separation signature predicts the prognosis and immunotherapy response in hepatocellular carcinoma.2024Journal of cellular and molecular medicine免费全文
  52. Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma.2024Scientific reports免费全文
  53. Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.2024Scientific reports免费全文
  54. Ablation alone is noninferior to radiotherapy plus ablation in the patients with early-stage hepatocellular carcinoma: a population-based study.2024Scientific reports免费全文
  55. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.2024Targeted oncology
  56. Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts.2024The British journal of radiology免费全文
  57. Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma.2024The British journal of radiology免费全文
  58. Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism.2024Theranostics免费全文
  59. Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study.2024Updates in surgery免费全文
  60. Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  61. Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study.2023Anti-cancer agents in medicinal chemistry免费全文
  62. A rare case of hepatocellular carcinoma supplied by the left internal mammary artery treated with transarterial chemoembolization.2023Asian journal of surgery
  63. Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.2023BMC cancer免费全文
  64. Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.2023BMC cancer免费全文
  65. TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma.2023BMC cancer免费全文
  66. Nuclear respiratory factor 1 drives hepatocellular carcinoma progression by activating LPCAT1-ERK1/2-CREB axis.2023Biology direct免费全文
  67. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  68. Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer Macrophages.2023Cellular and molecular gastroenterology and hepatology免费全文
  69. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  70. Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years.2023Clinical interventions in aging免费全文
  71. Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors.2023Clinics and research in hepatology and gastroenterology
  72. Comprehensive Treatment Uncertainty Analysis and PTV Margin Estimation for Fiducial Tracking in Robotic Liver Stereotactic Body Radiation Therapy.2023Current medical science
  73. Liver Transplantation Outcomes of HBV-, HCV-, and Alcohol-induced Hepatocellular Carcinoma in the United States: Analysis of National Inpatient Samples.2023Current medical science
  74. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.2023European journal of medical research免费全文
  75. Study on anxiety and depression in elderly patients with malignant liver tumor undergoing hepatectomy.2023European journal of medical research免费全文
  76. Validation and utility of HepG2 xenograft model for hepatocellular carcinoma.2023European journal of nuclear medicine and molecular imaging
  77. [177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy.2023European journal of nuclear medicine and molecular imaging
  78. A gadoxetic-acid enhancement flux analysis of small liver nodules (≤2 cm) in patients at high risk of hepatocellular carcinoma.2023European journal of radiology
  79. Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment.2023European journal of radiology
  80. A novel liver zonation phenotype-associated molecular classification of hepatocellular carcinoma.2023Frontiers in immunology免费全文
  81. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.2023Frontiers in immunology免费全文
  82. Diabetes and the risk of cirrhosis and HCC: An analysis of the UK Biobank.2023Hepatology communications免费全文
  83. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.2023International immunopharmacology
  84. FARSB Facilitates Hepatocellular Carcinoma Progression by Activating the mTORC1 Signaling Pathway.2023International journal of molecular sciences免费全文
  85. Deficiency of Carbamoyl Phosphate Synthetase 1 Engenders Radioresistance in Hepatocellular Carcinoma via Deubiquitinating c-Myc.2023International journal of radiation oncology, biology, physics
  86. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.2023Journal of experimental & clinical cancer research : CR免费全文
  87. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.2023Journal of nanobiotechnology免费全文
  88. Efficacy, mechanism, and safety of melatonin-loaded on thermosensitive nanogels for rabbit VX2 tumor embolization: A novel design.2023Journal of pineal research
  89. Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma.2023MedicineRCT免费全文
  90. Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study.2023Medicine免费全文
  91. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles.2023Oncoimmunology免费全文
  92. A novel fatty acid metabolism-related gene prognostic signature and candidate drugs for patients with hepatocellular carcinoma.2023PeerJ免费全文
  93. Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis.2023Scientific reports免费全文
  94. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: Etiological characteristics, treatment, and outcome analysis.2023The Kaohsiung journal of medical sciences免费全文
  95. The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma.2022Abdominal radiology (New York)
  96. The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus.2022Abdominal radiology (New York)
  97. Nanoscale CaO2 materials for synergistic transarterial chemoembolization in a VX2 orthotopic rabbit liver cancer model.2022Acta biomaterialia
  98. Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma.2022Aging免费全文
  99. Renal and hepatic artery embolization with Pickering gel emulsion of lipiodol in rabbit.2022BMC cancer免费全文
  100. MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells.2022BMC cancer免费全文
  101. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.2022BMC cancer免费全文
  102. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.2022BMC cancer免费全文
  103. Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis.2022Biochemical and biophysical research communications
  104. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.2022Cancer control : journal of the Moffitt Cancer Center免费全文
  105. Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE.2022Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  106. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.2022Cardiovascular and interventional radiology
  107. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.2022Cell reports
  108. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.2022Clinics and research in hepatology and gastroenterology
  109. Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors.2022Current medical science
  110. Application of Intravoxel Incoherent Motion in the Evaluation of Hepatocellular Carcinoma after Transarterial Chemoembolization.2022Current oncology (Toronto, Ont.)免费全文
  111. Perioperative factors related to the prognosis of elderly patients with hepatocellular carcinoma.2022European journal of medical research免费全文
  112. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617.2022European journal of nuclear medicine and molecular imaging免费全文
  113. Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing.2022Frontiers in endocrinology免费全文
  114. Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma.2022Hepatology communications免费全文
  115. The impact of particulate matter 2.5 on the risk of hepatocellular carcinoma: a meta-analysis.2022International archives of occupational and environmental health
  116. Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  117. Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.2022International journal of radiation oncology, biology, physics
  118. Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia.2022Journal for immunotherapy of cancer免费全文
  119. Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer.2022Mini reviews in medicinal chemistry
  120. Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.2022Molecular pharmaceutics
  121. The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus.2022Scientific reports免费全文
  122. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.2022Technology in cancer research & treatment免费全文
  123. Liver abscess after drug-eluting bead chemoembolization in patients with metastatic hepatic tumors.2022The British journal of radiology免费全文
  124. Crosstalk between macrophage-derived PGE2 and tumor UHRF1 drives hepatocellular carcinoma progression.2022Theranostics免费全文
  125. Effect of perioperative factors on the prognosis of patients with hepatocellular carcinoma who underwent hepatectomy.2022Turkish journal of medical sciences免费全文
  126. Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis.2021BMC cancer免费全文
  127. Integrated analysis of the functions and prognostic values of RNA binding proteins in hepatocellular carcinoma.2021BMC gastroenterology免费全文
  128. Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.2021BMC gastroenterology免费全文
  129. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.2021BMC gastroenterology免费全文
  130. Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients.2021BMC gastroenterology免费全文
  131. MicroRNA miR-495 regulates the development of Hepatocellular Carcinoma by targeting C1q/tumor necrosis factor-related protein-3 (CTRP3).2021Bioengineered免费全文
  132. Sublethal hyperthermia enhances anticancer activity of doxorubicin in chronically hypoxic HepG2 cells through ROS-dependent mechanism.2021Bioscience reports免费全文
  133. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study.2021Cancer medicine免费全文
  134. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma.2021Frontiers in immunology免费全文
  135. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.2021Hepatology international
  136. Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  137. Single sample scoring of hepatocellular carcinoma: A study based on data mining.2021International journal of immunopathology and pharmacology免费全文
  138. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.2021International journal of medical sciences免费全文
  139. Downregulation of hsa_circ_0074854 Suppresses the Migration and Invasion in Hepatocellular Carcinoma via Interacting with HuR and via Suppressing Exosomes-Mediated Macrophage M2 Polarization.2021International journal of nanomedicine免费全文
  140. Lenvatinib and Cu2-xS nanocrystals co-encapsulated in poly(D,L-lactide-co-glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma.2021Journal of materials chemistry. B
  141. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.2021Journal of nanobiotechnology免费全文
  142. Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy.2021Medicine免费全文
  143. Value of gadoxetic acid-enhanced MR imaging and DWI in classification, characterization and confidence in diagnosis of solid focal liver lesions.2021Scandinavian journal of gastroenterology
  144. Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization.2021Scientific reports免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
  1. Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma即将招募NCT07352345牵头方早期I期2026-01 启动
  2. Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus正在招募NCT07776080牵头方II期2026-10 启动
  3. Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE正在招募NCT07235410牵头方2025-11 启动
  4. Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)正在招募NCT07059936牵头方2025-07 启动
  5. HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma正在招募NCT06244225牵头方II期2024-01 启动
  6. Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma正在招募NCT06383520牵头方早期I期2023-09 启动
  7. Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma状态不明NCT05617430牵头方II期2022-11 启动
  8. Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma状态不明NCT05006326牵头方不分期2021-08 启动
  9. The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study状态不明NCT04909866牵头方II/III期2021-01 启动
  10. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  11. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk即将招募NCT07010588研究中心不分期2025-06 启动
  12. A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.正在招募NCT07052253研究中心II期2025-07 启动
  13. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  14. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  15. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  16. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  17. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)已完成NCT04740307研究中心II期2021-03 启动
  18. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  19. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  20. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)已完成NCT03867084研究中心III期2019-05 启动
  21. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  22. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)已完成NCT03713593研究中心III期2018-12 启动
  23. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  24. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation状态不明NCT03356236研究中心2018-04 启动
  25. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 78 篇,占 0.8%。

牵头论文
78
2021–2025 年
牵头试验
20
任何状态,ClinicalTrials.gov
牵头的开放试验
9
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 121220212022: 161620222023: 111120232024: 202020242025: 15152025

武汉有 5 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 15

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
    分期
    未注明
    开始
    2026-04
    登记号
    NCT07776067

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  2. 正在招募
    A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
    分期
    II期
    开始
    2025-02
    登记号
    NCT06685887

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  3. 正在招募
    Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07301814

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  4. 正在招募
    Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
    分期
    II期
    开始
    2025-07
    登记号
    NCT07920224

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  5. 正在招募
    Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
    分期
    II期
    开始
    2024-05
    登记号
    NCT06487429

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  6. 正在招募
    Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
    分期
    II期
    开始
    2024-11
    登记号
    NCT06826079

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  7. 即将招募
    Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
    分期
    II期
    开始
    2026-09
    登记号
    NCT07872696

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  8. 即将招募
    Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
    分期
    不分期
    开始
    2025-10
    登记号
    NCT07172503

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  9. 即将招募
    Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
    分期
    IV期
    开始
    2024-07
    登记号
    NCT05498766

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院;另有 1 家列出的医院为研究中心武汉、青岛

  10. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  11. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川

  12. 正在招募
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    分期
    I期
    开始
    2025-07
    登记号
    NCT07066657

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、哈尔滨、杭州、武汉、郑州、重庆、长沙

  13. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  14. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  15. 正在招募
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    分期
    I期
    开始
    2022-06
    登记号
    NCT05365581

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、杭州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物腹膜转移与晚期影像与人工智能
论文中的科室消化/肝病科病理/检验科影像/核医学科普外/肝胆胰外科
牵头的论文78
  1. Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Oxidative Stress Inflammation Score is the Optimal Inflammatory Prognostic Indicator for Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy: A Multicenter Retrospective Cohort Study.2026Annals of surgical oncology
  3. Association of different autoimmune diseases with gastric cancer incidence and risk: a global population-based analysis.2026International journal of surgery (London, England)
  4. Prognostic value of combined pathological response in primary tumor and lymph nodes after neoadjuvant chemoimmunotherapy for locally advanced gastric cancer.2026Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  5. Nortriptyline Inhibits Lysosomal Exocytosis-Mediated SASP During Gastric Cancer Progression via Targeting HOXA1-PITX2 Phase Separation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  6. Multi-omics analysis reveals disrupted gut microbiota and metabolism in gastric cancer patients with high SIRI.2025BMC cancer免费全文
  7. Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.2025BMC cancer免费全文
  8. Lipid accumulation product and visceral adiposity index as independent predictors of long-term survival after gastric cancer immunotherapy.2025BMC cancer免费全文
  9. Impact of intraoperative explanation combined with surgical video review on anatomy learning in laparoscopic distal gastrectomy.2025BMJ openRCT免费全文
  10. Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.2025Clinical epigenetics免费全文
  11. Prognostic value of [68Ga]Ga-FAPI-04 PET in patients with newly diagnosed gastric carcinoma.2025European journal of nuclear medicine and molecular imaging
  12. Which surrogate endpoint best predict survival in locally advanced gastric cancer patients undergoing neoadjuvant chemoimmunotherapy followed by surgery? A multicenter retrospective study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Establishment of an anaplastic stratification signature for gastric cancer based on diverse regulated cell-death.2025Frontiers in immunology免费全文
  14. Prognostic value of Naples prognostic score for locally advanced gastric cancer after neoadjuvant chemoimmunotherapy.2025Future oncology (London, England)免费全文
  15. SNORA37/CMTR1/ELAVL1 feedback loop drives gastric cancer progression via facilitating CD44 alternative splicing.2025Journal of experimental & clinical cancer research : CR免费全文
  16. Effectiveness of Snare Traction-Facilitated Endoscopic Resection for Gastric Submucosal Tumors ≥ 2 cm: A Propensity Score-Matched Study.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  17. USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer.2025Nature communications免费全文
  18. Advancements in non-invasive diagnosis of gastric cancer.2025World journal of gastroenterology免费全文
  19. Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy.2025World journal of surgical oncology免费全文
  20. ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.2024Annals of surgical oncology
  21. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.2024Annals of surgical oncology
  22. Lymph node ratio is a prognostic indicator for locally advanced gastric cancer after neoadjuvant immunochemotherapy.2024BMC gastroenterology免费全文
  23. Interleukin-6 on postoperative day three as an early predictor of infections following laparoscopic gastric cancer resection.2024BMC surgery免费全文
  24. Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.2024Cancer immunology, immunotherapy : CII免费全文
  25. Gut Roseburia is a protective marker for peritoneal metastasis of gastric cancer.2024Cancer medicine免费全文
  26. EIF2S2 transcriptionally upregulates HIF1α to promote gastric cancer progression via activating PI3K/AKT/mTOR pathway.2024Carcinogenesis
  27. Gamma-glutamyl transferase secreted by Helicobacter pylori promotes the development of gastric cancer by affecting the energy metabolism and histone methylation status of gastric epithelial cells.2024Cell communication and signaling : CCS免费全文
  28. Human gastric cancer progression and stabilization of ATG2B through RNF5 binding facilitated by autophagy-associated CircDHX8.2024Cell death & disease免费全文
  29. Immune checkpoints signature-based risk stratification for prognosis of patients with gastric cancer.2024Cellular signalling
  30. Case report metastatic SMARCB1 (INI1)-deficient gastric undifferentiated carcinoma in pleural effusion: A case report and literature review.2024Cytopathology : official journal of the British Society for Clinical Cytology
  31. CircMTA2 Drives Gastric Cancer Progression through Suppressing MTA2 Degradation via Interacting with UCHL3.2024International journal of molecular sciences免费全文
  32. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.2024International journal of surgery (London, England)免费全文
  33. Impact of Helicobacter pylori on immunotherapy in gastric cancer.2024Journal for immunotherapy of cancer免费全文
  34. The effect of surgery and metastatic risk prediction in patients with gastrointestinal tract signet-ring cell carcinoma.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  35. Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis.2024Journal of translational medicine免费全文
  36. Prognosis of EBV-positive gastric cancer with lymphoid stroma: systematic review and meta-analysis.2024Scandinavian journal of gastroenterology
  37. Helicobacter pylori CagA mediated mitophagy to attenuate the NLRP3 inflammasome activation and enhance the survival of infected cells.2024Scientific reports免费全文
  38. Analysis of clinicopathological characteristics and prognosis on primary gastric adenosquamous carcinoma.2024Scientific reports免费全文
  39. Identification of a lipid homeostasis-related gene signature for predicting prognosis, immunity, and chemotherapeutic effect in patients with gastric cancer.2024Scientific reports免费全文
  40. Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis.2023BMC gastroenterology免费全文
  41. Epigenetic and Tumor Microenvironment for Prognosis of Patients with Gastric Cancer.2023Biomolecules免费全文
  42. Microvesicles from bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by transferring thrombospondin-2.2023Cell communication and signaling : CCS免费全文
  43. Prediction of HER2 status via random forest in 3257 Chinese patients with gastric cancer.2023Clinical and experimental medicine
  44. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.2023Frontiers in immunology免费全文
  45. Exosome-Delivered circSTAU2 Inhibits the Progression of Gastric Cancer by Targeting the miR-589/CAPZA1 Axis.2023International journal of nanomedicine免费全文
  46. The impact of surgery and survival prediction in patients with gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.2023International journal of surgery (London, England)免费全文
  47. circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression.2023Journal of experimental & clinical cancer research : CR免费全文
  48. Bone mesenchymal stem cells promote gastric cancer progression through TGF-β1/Smad2 positive feedback loop.2023Life sciences
  49. Clinicopathological characteristics of mixed neuroendocrine-non-neuroendocrine neoplasms in gastrointestinal tract.2023Pathology, research and practice
  50. Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score matching.2023World journal of surgical oncology免费全文
  51. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment.2022AgingRCT免费全文
  52. Comparative Study of the Efficacy and Safety of Radical Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Gastric Cancer: A Propensity Score-Matching Analysis.2022Annals of surgical oncology
  53. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression.2022Autophagy免费全文
  54. Identification of miRNA biomarkers for stomach adenocarcinoma.2022BMC bioinformatics免费全文
  55. A dynamic predictive nomogram of long-term survival in primary gastric lymphoma: a retrospective study.2022BMC gastroenterology免费全文
  56. Effect of Postoperative ω-3 Fatty Acid Immunonutritional Therapy on NK Cell Gene Methylation in Elderly Patients with Gastric Cancer.2022Current medical scienceRCT
  57. Long noncoding RNA SNHG8 promotes chemoresistance in gastric cancer via binding with hnRNPA1 and stabilizing TROY expression.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  58. A new therapy for refractory gastric cancer bleeding: endoscopic ultrasound-guided lauromacrogol injection.2022Endoscopy
  59. The risk of aspirin induced postoperative hemorrhage: a systematic review and meta-analysis.2022Expert review of gastroenterology & hepatology
  60. LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  61. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.2022Gut免费全文
  62. Gamma-glutamyltransferase of Helicobacter pylori alters the proliferation, migration, and pluripotency of mesenchymal stem cells by affecting metabolism and methylation status.2022Journal of microbiology (Seoul, Korea)
  63. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT.2022Journal of nuclear medicine : official publication, Society of Nuclear Medicine免费全文
  64. Efficacy of local hemostatic agents after endoscopic submucosal dissection: a meta-analysis.2022Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  65. Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.2022Surgery
  66. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy.2022World journal of surgical oncology免费全文
  67. THBS4/integrin α2 axis mediates BM-MSCs to promote angiogenesis in gastric cancer associated with chronic Helicobacter pylori infection.2021Aging免费全文
  68. The New American Joint Committee on Cancer T staging system for stomach: increased complexity without clear improvement in predictive accuracy for endoscopic ultrasound.2021BMC gastroenterology免费全文
  69. Bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by secreting thrombospondin-2.2021Cell proliferation免费全文
  70. A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report.2021Frontiers in immunology免费全文
  71. CircGSK3B promotes RORA expression and suppresses gastric cancer progression through the prevention of EZH2 trans-inhibition.2021Journal of experimental & clinical cancer research : CR免费全文
  72. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.2021Journal of experimental & clinical cancer research : CR免费全文
  73. The Gamma-glutamyltransferase gene of Helicobacter pylori can promote gastric carcinogenesis by activating Wnt signal pathway through up-regulating TET1.2021Life sciences
  74. The Potential Role of IL1RAP on Tumor Microenvironment-Related Inflammatory Factors in Stomach Adenocarcinoma.2021Technology in cancer research & treatment免费全文
  75. Procalcitonin as an Early Predictor of Intra-abdominal Infections Following Gastric Cancer Resection.2021The Journal of surgical research
  76. PLAGL2 promotes the proliferation and migration of gastric cancer cells via USP37-mediated deubiquitination of Snail1.2021Theranostics免费全文
  77. Plexiform angiomyxoid myofibroblastic tumor treated by endoscopic submucosal dissection: A case report and review of the literature.2021World journal of gastroenterology免费全文
  78. Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis.2021mBio免费全文
中文论文(未计入)4
  1. [Application of totally laparoscopic right thoracic esophagojejunostomy in adenocarcinoma of the esophagogastric junction (AEG) surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Safety evaluation of hyperthermic intraperitoneal chemotherapy in patients with local advanced gastric cancer after radical resection for prevention of peritoneal metastasis].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Pay attention to misdiagnosis and differential diagnosis of gastric gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)48
  1. Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study即将招募NCT07872696牵头方II期2026-09 启动
  2. CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer正在招募NCT07776067牵头方2026-04 启动
  3. Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors正在招募NCT07301814牵头方2025-09 启动
  4. Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors即将招募NCT07172503牵头方不分期2025-10 启动
  5. A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis正在招募NCT06685887牵头方II期2025-02 启动
  6. Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma正在招募NCT07920224牵头方II期2025-07 启动
  7. Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer正在招募NCT06487429牵头方II期2024-05 启动
  8. Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients即将招募NCT05498766牵头方IV期2024-07 启动
  9. Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer正在招募NCT06826079牵头方II期2024-11 启动
  10. Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis状态不明NCT06487715牵头方II期2024-03 启动
  11. Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma状态不明NCT05625737牵头方II期2022-09 启动
  12. Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and Treatment状态不明NCT05426135牵头方2022-06 启动
  13. Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment状态不明NCT06653478牵头方2022-06 启动
  14. Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors状态不明NCT05527821牵头方II期2022-09 启动
  15. Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy状态不明NCT04808466牵头方II期2021-09 启动
  16. Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy状态不明NCT05029453牵头方IV期2021-08 启动
  17. Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC状态不明NCT04890392牵头方II期2021-01 启动
  18. A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy状态不明NCT05202236牵头方II期2021-10 启动
  19. Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer状态不明NCT04563975牵头方(推断)II期2020-07 启动
  20. A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery状态不明NCT02302794牵头方(推断)III期2014-08 启动
  21. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  22. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  23. A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors正在招募NCT07066657研究中心I期2025-07 启动
  24. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  25. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  26. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer正在招募NCT05365581研究中心I期2022-06 启动
  27. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)进行中,不再招募NCT06710132研究中心I/II期2025-01 启动
  28. A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors已完成NCT06549816研究中心I期2024-08 启动
  29. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  30. Development and Testing of a Social Cognitive Theory-based Dietary Behavioral Intervention in Gastric Cancer Survivors已完成NCT04985084研究中心不分期2022-01 启动
  31. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  32. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  33. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  34. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  35. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment已终止NCT04178460研究中心I期2020-02 启动
  36. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  37. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  38. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer已完成NCT04053205研究中心I/II期2019-11 启动
  39. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer已完成NCT04082364研究中心II/III期2019-09 启动
  40. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  41. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer状态不明NCT03273920研究中心不分期2017-09 启动
  42. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  43. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  44. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  45. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery状态不明NCT02130752研究中心不分期2014-10 启动
  46. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy状态不明NCT02110628研究中心III期2014-08 启动
  47. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动
  48. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer已终止NCT01641939研究中心II/III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

武汉有 5 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文1
  1. Current trends and prospects of surgical techniques for hepatoblastoma.2024Cancer medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma已完成NCT06190574牵头方2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

武汉有 18 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

武汉有 2 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
牵头的论文1
  1. Predicting overall survival in chordoma patients using machine learning models: a web-app application.2023Journal of orthopaedic surgery and research
早期论文(2016–2020 年)1
  1. Giant chordoma in the thoracolumbar spine: a case report and literature review.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 25 篇,占 1.1%。

牵头论文
25
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 8820222023: 3320232024: 5520242025: 662025

武汉有 31 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

这些论文过半是实验室或动物研究。

牵头的论文25
  1. Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal-Photodynamic-Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells.2025ACS nano
  2. Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment.2025Biomaterials
  3. Cancer-associated Fibroblast-like Cells Promote Osteosarcoma Metastasis by Upregulation of Phosphoserine Aminotransferase 1 and Activation of the mTOR/S6K Pathway.2025International journal of biological sciences
  4. GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape.2025Neoplasia (New York, N.Y.)
  5. KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1.2025Oncogene
  6. Signaling pathways and targeted therapies in Ewing sarcoma.2025Pharmacology & therapeutics
  7. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway.2024Aging
  8. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. Single-cell RNA sequencing reveals SERPINE1-expressing CAFs remodelling tumour microenvironment in recurrent osteosarcoma.2024Clinical and translational medicine
  10. Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA.2024Drug development research
  11. Biomimetic bone-periosteum scaffold for spatiotemporal regulated innervated bone regeneration and therapy of osteosarcoma.2024Journal of nanobiotechnology
  12. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.2023Journal of nanobiotechnology
  13. Network pharmacology-based research on the effect of Scutellaria baicalensis on osteosarcoma and the underlying mechanism.2023Medicine
  14. 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis.2023Molecular medicine (Cambridge, Mass.)
  15. Targeted Delivery of PD-L1-Derived Phosphorylation-Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment.2022Advanced healthcare materials
  16. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.2022BMC cancer
  17. SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma.2022Cell death & disease
  18. LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis.2022International journal of oncology
  19. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy.2022Journal of controlled release : official journal of the Controlled Release Society
  20. Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma.2022Molecular oncology
  21. Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1.2022Pharmacological research
  22. Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma.2022Theranostics
  23. CircRAB3IP upregulates twist family BHLH transcription factor (TWIST1) to promote osteosarcoma progression by sponging miR-580-3p.2021Bioengineered
  24. Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.2021Journal of clinical pharmacy and therapeutics
  25. Amplification of oxidative stress with lycorine and gold-based nanocomposites for synergistic cascade cancer therapy.2021Journal of nanobiotechnology
中文论文(未计入)1
  1. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].2022Zhonghua yi xue za zhi
早期论文(2016–2020 年)29
  1. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma.2020Acta biomaterialia
  2. Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis.2020BMC cancer
  3. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma.2020Colloids and surfaces. B, Biointerfaces
  4. Hsa_circ_0000285 functions as a competitive endogenous RNA to promote osteosarcoma progression by sponging hsa-miRNA-599.2020Gene therapy
  5. PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.2020Journal of cellular and molecular medicine
  6. LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway.2020Journal of cellular biochemistry
  7. Dysregulated circRNAs serve as prognostic and diagnostic markers in osteosarcoma by sponging microRNA to regulate the downstream signaling pathway.2020Journal of cellular biochemistry
  8. Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo.2020Journal of cellular physiology
  9. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity.2020Theranostics
  10. MiR-19a as a prognostic indicator for cancer patients: a meta-analysis.2019Bioscience reports
  11. Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis.2019Bioscience reports
  12. Bruceine D inhibits tumor growth and stem cell-like traits of osteosarcoma through inhibition of STAT3 signaling pathway.2019Cancer medicine
  13. Transcriptional activation of CBFβ by CDK11p110 is necessary to promote osteosarcoma cell proliferation.2019Cell communication and signaling : CCS
  14. Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma.2019Cell death & disease
  15. Integrative analyses of key genes and regulatory elements in fluoride-affected osteosarcoma.2019Journal of cellular biochemistry
  16. Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma.2019Journal of cellular physiology
  17. LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway.2019Journal of experimental & clinical cancer research : CR
  18. [Drug therapy of high grade osteosarcoma].2019Zhonghua yi xue za zhi
  19. The isolation, structural characterization and anti-osteosarcoma activity of a water soluble polysaccharide from Agrimonia pilosa.2018Carbohydrate polymers
  20. Reconstruction with constrained scapular prosthesis after total scapulectomy for scapular malignant tumor.2018Journal of surgical oncology
  21. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.2017Anti-cancer drugs
  22. Triggering of apoptosis in osteosarcoma cells by graphene/single-walled carbon nanotube hybrids via the ROS-mediated mitochondrial pathway.2017Journal of biomedical materials research. Part A
  23. In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/β-catenin signaling pathway in osteosarcoma.2017Medicine
  24. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.2017Oncotarget
  25. Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.2017Scientific reports
  26. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.2016Cancer chemotherapy and pharmacology
  27. Establishment and characterization of a novel osteosarcoma cell line: CHOS.2016Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  28. Clinical and biological significance of PIM1 kinase in osteosarcoma.2016Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  29. Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma.2016Journal of orthopaedic research : official publication of the Orthopaedic Research Society

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 18 篇,占 3.4%。

牵头论文
18
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 4420222023: 3320232024: 4420242025: 332025

武汉有 9 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    分期
    I期
    开始
    2018-07
    登记号
    NCT03594422

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、广州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科病理/检验科
牵头的论文18
  1. Distinguishing very high-risk patients among high-risk gastrointestinal stromal tumor cases: development and validation of a nomogram based on a multicenter population-based retrospective cohort study.2025Annals of medicine
  2. Imatinib adherence prediction using machine learning approach in patients with gastrointestinal stromal tumor.2025Cancer
  3. Is lymph node metastasis an advanced event of gastrointestinal stromal tumor?2025The oncologist
  4. Development of a simultaneous quantification method of imatinib and sunitinib and their main metabolites and its application in patients with gastrointestinal stromal tumor.2024Biomedical chromatography : BMC
  5. Intratumoral microbiome promotes liver metastasis and dampens adjuvant imatinib treatment in gastrointestinal stromal tumor.2024Cancer letters
  6. Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor.2024International immunopharmacology
  7. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.2024Journal of digestive diseases
  8. Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.2023Cancer research
  9. Cardiovascular-Specific Mortality among Gastrointestinal Stromal Tumor Patients: A Population-Based Analysis.2023Oxidative medicine and cellular longevity
  10. Anaplastic lymphoma kinase expression in PDGFRA-mutated gastrointestinal stromal tumors probably correlates with poor prognosis.2023World journal of surgical oncology
  11. Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.2022Advances in therapy
  12. Laparoscopic Versus Open Surgery for Rectal Gastrointestinal Stromal Tumor: A Multicenter Propensity Score-Matched Analysis.2022Diseases of the colon and rectumRCT
  13. Association between preoperative skeletal muscle mass depletion and poor relapse-free survival in patients with gastrointestinal stromal tumors after complete resection.2022Nutrition (Burbank, Los Angeles County, Calif.)
  14. Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.2022Surgery
  15. Duodenal gastrointestinal stromal tumors: A retrospective study based on a 13 years experience of a single center in China.2021Asia-Pacific journal of clinical oncology
  16. Radical resection versus local excision for low rectal gastrointestinal stromal tumor: A multicenter propensity score-matched analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.2021Journal of surgical oncology
  18. Efficacy of Endoscopic Ultrasound Elastography in Differential Diagnosis of Gastrointestinal Stromal Tumor Versus Gastrointestinal Leiomyoma.2021Medical science monitor : international medical journal of experimental and clinical research
中文论文(未计入)4
  1. [Analysis of the efficacy of adjusting the dose of imatinib with therapeutic drug monitoring in adjuvant treatment after complete resection of gastrointestinal stromal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Clinicopathological characteristics and prognosis of patients with sporadic multiple primary gastrointestinal stromal tumors].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Pay attention to misdiagnosis and differential diagnosis of gastric gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
早期论文(2016–2020 年)17
  1. Elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis of patients with primary gastrointestinal stromal tumor.2020BMC gastroenterology
  2. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.2020Diagnostic pathology
  3. Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts.2020EBioMedicine
  4. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.2020Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  5. Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors: a Propensity Score Matching Analysis.2020Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  6. Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis.2020The Journal of surgical research
  7. [Characteristics and targeted therapy of wild-type gastrointestinal stromal tumor].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [A model to predict the recurrence of middle-high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. The prognostic value of gastrointestinal bleeding in gastrointestinal stromal tumor: A propensity score matching analysis.2019Cancer medicine
  10. Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.2019Chemotherapy
  11. A Population-Based Study of the Incidence and Survival of Anorectal Gastrointestinal Stromal Tumor.2019Medical science monitor : international medical journal of experimental and clinical research
  12. [Laparoscopic versus open surgery for gastric gastrointestinal stromal tumors in unfavorable location: a propensity score-matching analysis].2019Zhonghua wai ke za zhi [Chinese journal of surgery]
  13. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. Clinicopathological and Prognostic Analysis of Primary Gastrointestinal Stromal Tumor Presenting with Gastrointestinal Bleeding: a 10-Year Retrospective Study.2017Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  15. Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: A single-institutional experience in China.2017Medicine
  16. Clinicopathologic features and prognosis of primary gastrointestinal stromal tumor patients under 35 years of age: A 10-year retrospective study.2016Journal of surgical oncology
  17. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  2. A Study of HQP1351 in Patients With GIST or Other Solid Tumors正在招募NCT03594422研究中心I期2018-07 启动
  3. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动
  4. A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor已完成NCT04254939研究中心I/II期2019-08 启动
  5. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.7%。

牵头论文
8
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 3320232024: 2220242025: 112025

武汉有 11 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室儿科神经内科

这些论文过半是实验室或动物研究。

牵头的论文8
  1. Targeting RBM10-Repressed RORB Activity in Liquid Condensates Inhibits Lysosomal Biogenesis and Neuroblastoma Progression via Affecting NF-κB Signaling.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Targeting c-Myc transactivation by LMNA inhibits tRNA processing essential for malate-aspartate shuttle and tumour progression.2024Clinical and translational medicine
  3. YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression.2024Journal of translational medicine
  4. Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity.2023Clinical and translational medicine
  5. SIRT3 ameliorates diabetes-associated cognitive dysfunction via regulating mitochondria-associated ER membranes.2023Journal of translational medicine
  6. Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity.2023Oncogene
  7. HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation.2022Oncogene
  8. Lead exposure represses mitochondrial metabolism by activation of heme-binding protein BACH1 in differentiated SH-SY5Y cell.2022The Science of the total environment
早期论文(2016–2020 年)13
  1. Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.2020Molecular therapy : the journal of the American Society of Gene Therapy
  2. Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.2020Theranostics
  3. SNW1 regulates Notch signaling in neuroblastoma through interacting with RBPJ.2019Biochemical and biophysical research communications
  4. Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma.2019Biochemical and biophysical research communications
  5. Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression.2019EMBO molecular medicine
  6. Long Noncoding RNA pancEts-1 Promotes Neuroblastoma Progression through hnRNPK-Mediated β-Catenin Stabilization.2018Cancer research
  7. DAPK1-ERK signal mediates oxygen glucose deprivation reperfusion induced apoptosis in mouse N2a cells.2018Journal of the neurological sciences
  8. Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4.2018Nature communications
  9. Overexpression of Tau Rescues Nogo-66-Induced Neurite Outgrowth Inhibition In Vitro.2016Neuroscience bulletin
  10. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.2016Oncogene
  11. microRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5'-untranslated region in neuroblastoma.2016Oncotarget
  12. Smad4 suppresses the tumorigenesis and aggressiveness of neuroblastoma through repressing the expression of heparanase.2016Scientific reports
  13. Risk stratification and therapeutics of neuroblastoma: the challenges remain.2016World journal of pediatrics : WJP
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma已完成NCT06190574牵头方2021-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

武汉有 6 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 30 篇,占 1.8%。

牵头论文
30
2021–2025 年
牵头试验
10
任何状态,ClinicalTrials.gov
牵头的开放试验
5
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 3320222023: 7720232024: 9920242025: 662025

武汉有 3 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
    分期
    早期I期
    开始
    2026-03
    登记号
    NCT07429721

    年龄 18 岁 至 未注明(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  2. 正在招募
    An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
    分期
    早期I期
    开始
    2025-09
    登记号
    NCT07101705

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  3. 正在招募
    The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
    分期
    未注明
    开始
    2024-04
    登记号
    NCT06228794

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  4. 正在招募
    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
    分期
    II期
    开始
    2023-10
    登记号
    NCT06140966

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  5. 即将招募
    Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
    分期
    III期
    开始
    2025-09
    登记号
    NCT06580223

    年龄 18 岁 至 90 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  6. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  7. 正在招募
    LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
    分期
    不分期
    开始
    2025-09
    登记号
    NCT07100067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、天津、武汉

  8. 正在招募
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2024-06
    登记号
    NCT06508983

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州

  9. 正在招募
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06049290

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、厦门、太原、宁波、广州、杭州、武汉、沈阳、海口、深圳、温州、苏州、西安、贵阳、郑州、长春、青岛

  10. 正在招募
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    分期
    I/II期
    开始
    2023-10
    登记号
    NCT06182696

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、南京、杭州、武汉

  11. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层CAR-T 与细胞治疗双抗与抗体药物
论文中的科室影像/核医学科
牵头的论文30
  1. Global burden of multiple myeloma in older adults from 1990 to 2021 and modeled projection to 2050.2026International journal of surgery (London, England)
  2. Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  3. Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.2025Annals of medicine免费全文
  4. Integrating single-cell and bulk RNA profiles to uncover glutamine metabolism's role in prognosis and immune dynamics in multiple myeloma.2025BMC cancer免费全文
  5. Macrophage migration inhibitory factor as a prognostic biomarker in multiple myeloma: clinical significance and in vitro effects.2025Carcinogenesis
  6. ZNF655 involved in the progression of multiple myeloma via the activation of AKT.2025Cell biology international
  7. Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma.2025Journal of translational medicine免费全文
  8. ALKHB5-demethylated lncRNA SNHG15 promotes myeloma tumorigenicity by increasing chromatin accessibility and recruiting H3K36me3 modifier SETD2.2024American journal of physiology. Cell physiology免费全文
  9. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.2024Annals of medicine免费全文
  10. Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.2024Blood advances免费全文
  11. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.2024Frontiers in bioscience (Landmark edition)
  12. Different evasion strategies in multiple myeloma.2024Frontiers in immunology免费全文
  13. GLYR1 transcriptionally regulates PER3 expression to promote the proliferation and migration of multiple myeloma.2024Genomics
  14. Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis.2024International immunopharmacology
  15. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.2024Leukemia免费全文
  16. Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?2024The Lancet. Haematology
  17. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.2023Annals of medicine免费全文
  18. Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report.2023British journal of haematology
  19. MALAT1 regulates network of microRNA-15a/16-VEGFA to promote tumorigenesis and angiogenesis in multiple myeloma.2023Carcinogenesis
  20. ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis.2023Carcinogenesis
  21. CCL18 promotes migration and invasion of multiple myeloma cells and is associated with poor prognosis.2023Carcinogenesis
  22. A prognostication system based on clinical parameters and [18F]-FDG PET/CT in patients with newly diagnosed multiple myeloma.2023European journal of nuclear medicine and molecular imaging
  23. The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis.2023Technology and health care : official journal of the European Society for Engineering and Medicine
  24. Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma.2022Frontiers in immunology免费全文
  25. ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype.2022International journal of biological sciences免费全文
  26. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner.2022Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  27. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.2021International immunopharmacology
  28. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.2021Journal of hematology & oncology免费全文
  29. JunB is a key regulator of multiple myeloma bone marrow angiogenesis.2021Leukemia免费全文
  30. COVID-19 in patients with multiple myeloma: a cross-sectional survey from the most severely affected region in China.2021Leukemia & lymphoma
中文论文(未计入)5
  1. [Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [BCMA/CS1 bispecific CAR-T cell therapy for multiple myeloma complicated with thrombocytopenia: a case report and literature review].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  3. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  4. [Update on biology of primary plasma cell leukemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  5. [Clinical characteristics of patients with multiple myeloma harboring 6q deletion].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)29
  1. A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.正在招募NCT07429721牵头方早期I期2026-03 启动
  2. Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma即将招募NCT06580223牵头方III期2025-09 启动
  3. An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies正在招募NCT07101705牵头方早期I期2025-09 启动
  4. The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial正在招募NCT06228794牵头方2024-04 启动
  5. Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma正在招募NCT06140966牵头方II期2023-10 启动
  6. Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM状态不明NCT06503107牵头方I/II期2024-04 启动
  7. A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.已暂停NCT06691685牵头方早期I期2024-11 启动
  8. A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy状态不明NCT05998928牵头方II期2023-07 启动
  9. Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies状态不明NCT05672420牵头方I/II期2023-01 启动
  10. T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma状态不明NCT04662099牵头方I期2020-03 启动
  11. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  12. LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma正在招募NCT07100067研究中心不分期2025-09 启动
  13. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients正在招募NCT06508983研究中心III期2024-06 启动
  14. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma正在招募NCT06049290研究中心I/II期2023-10 启动
  15. OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM正在招募NCT06182696研究中心I/II期2023-10 启动
  16. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  17. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  18. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  19. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  20. A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma已终止NCT05590377研究中心I/II期2023-01 启动
  21. ATG-010(Selinexor) in Combination With Chemotherapy in RRMM状态不明NCT04877275研究中心II期2021-05 启动
  22. Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma状态不明NCT05346198研究中心I期2021-03 启动
  23. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma状态不明NCT04674514研究中心I/II期2021-04 启动
  24. Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma状态不明NCT04861480研究中心I期2021-06 启动
  25. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  26. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  27. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  28. Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications已完成NCT02649790研究中心I/II期2016-01 启动
  29. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)已终止NCT01947309研究中心2013-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.3%。

牵头论文
3
2021–2025 年
牵头试验
7
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
7
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

武汉有 3 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 9

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
    分期
    早期I期
    开始
    2026-04
    登记号
    NCT07470073

    年龄 12 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  2. 正在招募
    CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
    分期
    I/II期
    开始
    2024-11
    登记号
    NCT06735495

    年龄 3 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

  3. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  4. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

  5. 正在招募
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    分期
    III期
    开始
    2025-03
    登记号
    NCT07152041

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛

  6. 正在招募
    The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
    分期
    早期I期
    开始
    2024-03
    登记号
    NCT06307600

    年龄 3 岁 至 70 岁(登记的条件)

    牵头:中国科学技术大学附属第一医院(安徽省立医院);另有 1 家列出的医院为研究中心合肥、武汉

  7. 正在招募
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    分期
    未注明
    开始
    2024-06
    登记号
    NCT06450067

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、天津、广州、徐州、成都、武汉、济南、郑州

  8. 正在招募
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05667506

    年龄 3 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心南京、南昌、合肥、天津、广州、徐州、武汉、重庆

  9. 正在招募
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    分期
    I/II期
    开始
    2022-11
    登记号
    NCT05579132

    年龄 2 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心天津、广州、徐州、成都、杭州、武汉、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题CAR-T 与细胞治疗儿童副作用(细胞因子释放综合征、神经毒性)
论文中的科室肿瘤内科
牵头的论文3
  1. Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia.2025Current medical science免费全文
  2. Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review.2025Frontiers in immunology免费全文
  3. Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.2025Thrombosis research
中文论文(未计入)2
  1. [The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  2. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)19
  1. A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults正在招募NCT07470073牵头方早期I期2026-04 启动
  2. CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors正在招募NCT06735495牵头方I/II期2024-11 启动
  3. CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors状态不明NCT06503094牵头方I/II期2024-01 启动
  4. Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies进行中,不再招募NCT06220097牵头方II期2022-02 启动
  5. Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies状态不明NCT04796675牵头方I期2021-04 启动
  6. Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies状态不明NCT04796688牵头方I期2021-03 启动
  7. Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies状态不明NCT04007978牵头方I期2019-08 启动
  8. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol正在招募NCT06764238研究中心II/III期2025-01 启动
  9. Newly-diagnosed Pediatric Ph-positive B-ALL Protocol正在招募NCT07152041研究中心III期2025-03 启动
  10. Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol正在招募NCT06882057研究中心II/III期2025-03 启动
  11. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia正在招募NCT06450067研究中心2024-06 启动
  12. The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia正在招募NCT06307600研究中心早期I期2024-03 启动
  13. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)正在招募NCT05667506研究中心I/II期2023-02 启动
  14. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)正在招募NCT05579132研究中心I/II期2022-11 启动
  15. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL进行中,不再招募NCT04521231研究中心I/II期2021-01 启动
  16. Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies状态不明NCT04008251研究中心I期2019-05 启动
  17. Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies状态不明NCT03366350研究中心I/II期2016-04 启动
  18. Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies状态不明NCT03366324研究中心I/II期2016-05 启动
  19. CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies状态不明NCT02965092研究中心I/II期2015-12 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

武汉有 4 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07552506

    年龄 14 岁 至 50 岁;仅女性(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院;另有 3 家列出的医院为研究中心杭州、武汉、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫抑制治疗儿童
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 8 篇,占 2.0%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 3320242025: 332025

武汉有 2 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题EB病毒与感染诱因治疗方案淋巴瘤及肿瘤相关噬血
论文中的科室儿科肿瘤内科
牵头的论文8
  1. Development and validation of a predictive model for diagnosing EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis.2025BMC cancer免费全文
  2. C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China.2025Blood advances免费全文
  3. Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies.2025Expert review of clinical immunology
  4. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.2024International journal of pharmaceutics
  5. Clinical utility of plasma Epstein-Barr virus DNA monitoring in pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: a Chinese retrospective observational study.2024Italian journal of pediatrics免费全文
  6. Clinical significance and different strategies for re-elevation of plasma EBV-DNA during treatment in pediatric EBV-associated hemophagocytic lymphohistiocytosis.2024Jornal de pediatria免费全文
  7. Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis complicated by neurological involvement in a patient with dermatomyositis: A case report and literature review.2023Modern rheumatology case reports
  8. Hemophagocytic lymphohistiocytosis after COVID-19 vaccination.2021Journal of hematology & oncology免费全文
中文论文(未计入)1
  1. [Clinical Characteristics and Prognosis of Children with Hematological Malignancies Complicated by Secondary Hemophagocytic Lymphohistiocytosis].2025Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])正在招募NCT07208058研究中心III期2025-11 启动
PubMed 以外找到的论文(未计入)3
  1. CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.2024Journal of Clinical Oncology会议摘要
  2. Clinical features and prognostic factors of adult patients with hemophagocytic lymphohistiocytosis: a retrospective study of 130 adult patients2022Research Square预印本
  3. Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma2022International Journal of Radiation Oncology*Biology*Physics论文

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

武汉有 2 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    分期
    III期
    开始
    2025-03
    登记号
    NCT06833983

    年龄 18 岁 至 65 岁;仅男性(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心兰州、北京、南京、南昌、合肥、唐山、天津、广州、昆明、武汉、济南、郑州、长沙

  2. 正在招募
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    分期
    II/III期
    开始
    2024-01
    登记号
    NCT06111638

    年龄 18 岁 至 未注明;仅男性(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心Xi’an、北京、天津、广州、成都、昆明、武汉、苏州、贵阳、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文1
  1. RNAi targeting heparin cofactor II promotes hemostasis in a canine model of acquired hemophilia A.2025Gene therapy
早期论文(2016–2020 年)2
  1. Combined deficiency of factors V and VIII in a Chinese family due to a novel nonsense mutation in lectin mannose binding protein 1.2020International journal of laboratory hematology
  2. Acquired hemophilia A in a woman with systemic lupus erythematosus: A case report and review of literature.2020Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A正在招募NCT06833983研究中心III期2025-03 启动
  2. Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs正在招募NCT06111638研究中心II/III期2024-01 启动
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.进行中,不再招募NCT07684898研究中心III期2026-06 启动
  4. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  5. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  6. To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A进行中,不再招募NCT07548411研究中心I/II期2023-07 启动
  7. China ADVATE PTP Study已完成NCT02170402研究中心IV期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

武汉有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

武汉有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年没有牵头IgG4相关性疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases已撤回NCT07583030牵头方早期I期2026-09 启动
PubMed 以外找到的论文(未计入)1
  1. Potential roles of antibodies with different classes in IgG4‐related diseases2025Rheumatology & autoimmunity论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年没有牵头重症肌无力的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 3 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
    分期
    不分期
    开始
    2026-03
    登记号
    NCT07470151

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases正在招募NCT07470151牵头方不分期2026-03 启动
  2. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases已撤回NCT07583030牵头方早期I期2026-09 启动
  3. A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases已撤回NCT06869278牵头方I期2025-06 启动
  4. Study of Telitacicept in Generalized Myasthenia Gravis已完成NCT05737160研究中心III期2023-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.6%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

武汉有 3 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题遗传
论文中的科室神经外科
牵头的论文2
  1. Progress in the application of stem cell therapy for moyamoya disease.2025Biochemical and biophysical research communications
  2. Identification of the potential role of S1PR1 in adult moyamoya disease based on multiple bioinformatics analysis and experimental verification.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
PubMed 以外找到的论文(未计入)1
  1. Mycoplasma pneumoniae-associated cerebral infarction in a child: A case report and literature review2025Medicine Case Reports and Study Protocols论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

胆道闭锁

Biliary atresia

2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 7 篇,占 3.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 1120242025: 442025

武汉有 2 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。

这些数字背后的记录
研究主题Kasai手术长期结局筛查与诊断
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

武汉有 5 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科
牵头的论文2
  1. Decoding NMDAR encephalitis: proteomic markers and computational identification of potential therapeutic pathways.2025Brain, behavior, and immunity
  2. Intrathecal treatment of Anti-N-Methyl-D-Aspartate receptor encephalitis: a promising approach for refractory cases.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

武汉有 4 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
牵头的论文1
  1. Multiple Aneurysms of the Subclavian-Axillary, Abdominal Aortoiliac, Lower Extremity, and Coronary Arteries in A Pediatric Patient of Takayasu Arteritis.2022Annals of vascular surgery
早期论文(2016–2020 年)1
  1. Involvement of the Bicuspid Aortic Valve Mimicking a Mass in Takayasu Arteritis.2018Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis即将招募NCT07451665研究中心IV期2026-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

武汉有 9 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
牵头的论文3
  1. Pre-exposure to Aerosolized Polyvalent Bacterial Lysates Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice.2022Inflammation
  2. Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis.2022Journal of cellular physiology
  3. VEGF/Src signaling mediated pleural barrier damage and increased permeability contributes to subpleural pulmonary fibrosis.2021American journal of physiology. Lung cellular and molecular physiology
早期论文(2016–2020 年)3
  1. Cigarette smoking aggravates bleomycin-induced experimental pulmonary fibrosis.2019Toxicology letters
  2. Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats.2018Medical science monitor : international medical journal of experimental and clinical research
  3. miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II.2017Molecular therapy : the journal of the American Society of Gene Therapy
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  4. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT05321069研究中心III期2022-10 启动
  5. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT04419558研究中心III期2020-09 启动
  6. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年没有牵头肌萎缩侧索硬化症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 6 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD.2018Cell death and differentiation

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 7 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.3%。

牵头论文
2
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

武汉有 8 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of YKST02 in Participants With Primary IgA Nephropathy
    分期
    早期I期
    开始
    2026-05
    登记号
    NCT07498673

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:华中科技大学同济医学院附属协和医院武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肾内科
牵头的论文2
  1. Causal association between peripheral immune cells and IgA nephropathy: a Mendelian randomization study.2024Frontiers in immunology
  2. Research advances on targeted-Treg therapies on immune-mediated kidney diseases.2023Autoimmunity reviews
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of YKST02 in Participants With Primary IgA Nephropathy正在招募NCT07498673牵头方早期I期2026-05 启动
  2. Model Development and Application Based on Renal Pathology Images进行中,不再招募NCT07816874牵头方2019-01 启动
  3. TESTING -ON Post-Trial ObservatioNal Cohort Study已完成NCT05434325研究中心2022-12 启动
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)已完成NCT01560052研究中心不分期2012-05 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

武汉有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 112025

武汉有 5 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 3 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

武汉有 1 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文1
  1. Multimodality Imaging of Congenital Intrapericardial Diaphragmatic Hernia.2024Radiology. Cardiothoracic imaging

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 8 篇,占 5.0%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 0020242025: 332025

武汉有 3 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文8
  1. Tight junction dysfunction and cytoskeletal remodeling in Hirschsprung‑associated enterocolitis: A decade of mechanistic insights and therapeutic prospects (Review).2026Molecular medicine reports
  2. Robotic-assisted Proctosigmoidectomy Versus Laparoscopic-assisted Soave Pull-through for Hirschsprung Disease: Medium-term Outcomes From a Prospective Multicenter Study.2025Annals of surgery
  3. Whole-genome sequencing identified ALK as a novel susceptible gene of Hirschsprung disease.2025Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  4. Secretagogin Downregulation Impairs Nerve Cell Migration in Hirschsprung Disease via Inhibition of the LEF-1/NCAM1 Axis.2025Molecular & cellular proteomics : MCP
  5. Update on the Pathogenesis of the Hirschsprung-Associated Enterocolitis.2023International journal of molecular sciences
  6. Robotic-assisted proctosigmoidectomy for Hirschsprung's disease: A multicenter prospective study.2023World journal of gastroenterology
  7. Hirschsprung's disease: key microRNAs and target genes.2022Pediatric research
  8. Skip segment Hirschsprung's disease: diagnostic clues and surgical management.2021Pediatric surgery international
早期论文(2016–2020 年)12
  1. Resuturing Without Enterostomy for the Treatment of Early-Stage Anastomotic Leaks After Laparoscopic Soave Procedure in Hirschsprung's Disease.2020Journal of laparoendoscopic & advanced surgical techniques. Part A
  2. Primary laparoscopic endorectal pull-through procedure with or without a postoperative rectal tube for hirschsprung disease: a multicenter perspective study.2020Journal of pediatric surgeryRCT
  3. Laparoscopic Redo Pull-Through for Hirschsprung Disease Due to Innervation Disorders.2019Journal of laparoendoscopic & advanced surgical techniques. Part A
  4. Increased miR-214 expression suppresses cell migration and proliferation in Hirschsprung disease by interacting with PLAGL2.2019Pediatric research
  5. Transumbilical enterostomy for Hirschsprung's disease with a two-stage laparoscopy-assisted pull-through procedure.2019World journal of gastroenterology
  6. Duhamel operation vs. transanal endorectal pull-through procedure for Hirschsprung disease: A systematic review and meta-analysis.2018Journal of pediatric surgery
  7. Laparoscopic-assisted Duhamel procedure with ex-anal rectal transection for total colonic aganglionosis.2018Journal of pediatric surgery
  8. Gli family zinc finger 1 is associated with endothelin receptor type B in Hirschsprung disease.2018Molecular medicine reports
  9. Laparoscopic Duhamel Procedure with Ex-Anal Rectal Transection for Right-Sided Hirschsprung's Disease.2017Journal of laparoendoscopic & advanced surgical techniques. Part A
  10. Neuregulin 1 is involved in enteric nervous system development in zebrafish.2017Journal of pediatric surgery
  11. Effects of NRG1 Polymorphisms on Hirschsprung's Disease Susceptibility: A Meta-analysis.2017Scientific reports
  12. Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease.2017Scientific reports

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

武汉有 4 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

华中科技大学同济医学院附属协和医院

Union Hospital

武汉

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Wuhan Union Hospital; Union Hospital of Tongji Medical College; Huazhong University of Science and Technology; Union Hospital Tongji Medical College; Union Hospital Wuhan; Union Hospital of Huazhong University of Science and Technology; Union Hospital Affiliated to Tongji Medical College; Tongji Medical College Union Hospital

提出更正下载数据